Favezelimab is under clinical development by Merck and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Favezelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Favezelimab (MK-4280) is under development for the treatment of non-small cell lung cancer, colorectal cancer, gastric cancer and hematologic malignancies includes classical Hodgkin lymphoma, diffuse large B-cell lymphoma, indolent non-Hodgkin lymphoma, primary mediastinal b-cell lymphoma, follicular lymphoma, marginal zone b-cell lymphoma, waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), chronic lymphocytic leukemia and advanced solid tumors. The drug candidate is administered as intravenous infusion. It is a humanized IgG4 monoclonal antibody (mAb) that acts by targeting LAG3.
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
For a complete picture of Favezelimab’s drug-specific PTSR and LoA scores, buy the report here.